ANA Pattern Test

If your body's immune system has started making antibodies against your own cells, knowing that those antibodies exist is only half the story. The ANA (antinuclear antibody) pattern tells you what those antibodies are actually targeting, and that distinction can mean the difference between a reassuring finding and an early warning of lupus, scleroderma, or autoimmune liver disease.

A positive ANA result is common. Roughly 10 to 15% of healthy adults will test positive at a 1:80 screening dilution, and most of them will never develop an autoimmune condition. The pattern is what separates the signal from the noise. Certain patterns strongly predict specific diseases, while others, like the dense fine speckled pattern, are actually more common in healthy people than in those with autoimmune illness.

How the Test Works

The lab places a drop of your blood serum onto a slide coated with a standard line of human cells called HEp-2 cells. If your blood contains antibodies that attack cellular structures, those antibodies bind to the cells. A fluorescent dye is added so the lab can see where the antibodies attached. The shape and location of the glow under a microscope is the "pattern." Different patterns correspond to different molecular targets inside the cell.

An international system called ICAP (International Consensus on ANA Patterns) standardizes these patterns using alphanumeric codes. The main categories are nuclear patterns (antibodies targeting structures inside the cell's command center), cytoplasmic patterns (targeting structures outside the nucleus but inside the cell), and mitotic patterns (targeting structures that appear when cells divide).

What Each Major Pattern Means

Not all patterns carry equal clinical weight. Some are strongly linked to specific diseases, while others have weak or unclear associations. Here are the patterns that matter most.

• Homogeneous (AC-1): Antibodies target DNA and the protein spools it wraps around (called histones and nucleosomes). This pattern is strongly linked to lupus (SLE) and autoimmune hepatitis. In a study of 495 SLE patients, homogeneous was among the most common patterns and correlated with higher anti-dsDNA antibodies and lower complement levels, both markers of more active disease.
• Speckled (AC-4/AC-5): Antibodies target various proteins involved in processing genetic information. This is the most commonly seen pattern overall. Fine speckled and coarse speckled variants point toward lupus, Sjogren's syndrome, mixed connective tissue disease, or scleroderma, depending on which specific protein the antibodies recognize.
• Dense fine speckled (AC-2): This pattern targets a protein called DFS70. In a community hospital study of over 6,500 samples, isolated DFS70 antibodies were found frequently, and their presence was reassuring. When this pattern appeared without other specific autoantibodies, systemic autoimmune rheumatic disease was unlikely.
• Centromere (AC-3): Antibodies target the part of chromosomes where they attach during cell division. This pattern is characteristic of limited scleroderma (systemic sclerosis) and can also appear in primary biliary cholangitis, a type of autoimmune liver disease.
• Nucleolar (AC-8/9/10): Antibodies target structures in the part of the nucleus that builds cellular machinery. This pattern is associated with scleroderma, and in a study of 31,815 samples, it was also linked to a roughly 50% higher risk of cancer compared to other patterns.
• Cytoplasmic reticular (AC-21): Antibodies target structures in the energy-producing compartments of cells (mitochondria). This pattern strongly signals primary biliary cholangitis and other autoimmune liver diseases. In a study of 196 patients with suspected autoimmune liver disease, the reticular cytoplasmic pattern was the strongest indicator of the diagnosis.

Lupus (SLE)

A positive ANA is now an entry criterion for classifying lupus. In a study of 495 SLE patients, peripheral, mixed, and speckled patterns were associated with the most aggressive immune profiles, including higher anti-dsDNA antibodies, lower complement (proteins that help clear immune waste), and the presence of antiphospholipid antibodies, which raise clotting risk. Patients with these patterns tended to have more immunologically active disease.

Machine learning analysis of 805 SLE patients tracked over 10 years identified four distinct autoantibody clusters. Those with high anti-Sm/U1RNP antibodies and large nuclear speckled patterns had the highest disease activity, required the most intensive treatment, and had worse survival. This reinforces that pattern is not just a label; it carries prognostic information.

Rheumatoid Arthritis

About 40% of people with rheumatoid arthritis (RA) test ANA-positive. In a study of 2,837 participants, ANA positivity was associated with increased RA risk, and the homogeneous pattern showed the strongest association. A registry of 814 RA patients found that those with a nucleolar ANA pattern were independently more likely to develop interstitial lung disease, a serious complication affecting the lungs.

Scleroderma (Systemic Sclerosis)

ANA patterns are especially useful in scleroderma because different patterns map to different disease subtypes. In a study of 150 scleroderma patients, patterns targeting an enzyme called topoisomerase I correlated with diffuse skin disease, lung scarring (interstitial lung disease), pulmonary hypertension, and Raynaud's phenomenon (painful cold sensitivity in the fingers). Centromere patterns pointed toward limited skin involvement. Nucleolar patterns, combined with antihistone antibodies (antibodies targeting the protein spools that DNA wraps around), were linked to heart enlargement, broader organ involvement, and reduced survival in a study of 276 patients.

Autoimmune Liver Disease

The cytoplasmic reticular pattern is a standout finding for autoimmune liver disease, especially primary biliary cholangitis (PBC). This pattern reflects antibodies targeting mitochondrial proteins and is strongly associated with positive antimitochondrial antibody testing. In suspected autoimmune liver disease, this pattern can be clinically meaningful even when the nuclear ANA itself is negative.

For autoimmune hepatitis specifically, a homogeneous ANA pattern combined with anti-nucleosome antibodies (antibodies targeting the DNA-protein complex) provided high accuracy in distinguishing true autoimmune hepatitis from drug-induced liver injury in a study of 81 patients.

Cancer Associations

In a large study of over 31,000 samples, people with a nucleolar ANA pattern had a roughly 50% higher relative risk of cancer compared to those without ANA. By contrast, homogeneous and speckled patterns were associated with a lower cancer risk. This does not mean a nucleolar pattern diagnoses cancer, but it may warrant additional attention, especially if other risk factors are present.

The Dense Fine Speckled Exception

If your report shows an isolated dense fine speckled (DFS70/AC-2) pattern without other specific autoantibodies, that is generally good news. In a community hospital study of 6,511 ANA tests, anti-DFS70 antibodies were common and rarely associated with systemic autoimmune rheumatic disease. This pattern is actually more prevalent in healthy individuals than in patients with conditions like lupus. If your pattern is DFS70 and you have no symptoms, the result is largely reassuring.

Titer Matters as Much as Pattern

The titer (reported as a dilution like 1:80, 1:160, or 1:320) tells you how concentrated the antibodies are in your blood. Higher titers make autoimmune disease more likely. In a meta-analysis evaluating ANA performance for classifying lupus, a titer of 1:80 caught about 98% of SLE cases but flagged many healthy people too. At 1:160, sensitivity was still about 96% but specificity jumped to about 86%. At 1:320, specificity reached roughly 97%, meaning very few healthy people would test positive at that level.

In a study of over 10,000 samples, the combination of pattern and titer dramatically changed the likelihood of having an autoimmune rheumatic disease. A low-titer speckled pattern had modest predictive value, while a high-titer centromere or homogeneous pattern carried much stronger disease associations.

These thresholds come from large population studies and international guidelines, not from a single lab. Your own lab may use slightly different cutpoints depending on their equipment and reagents. Always compare your results within the same lab over time.

When Results Can Be Misleading

ANA pattern interpretation has real limitations that can lead to incorrect conclusions.

• Lab-to-lab variation: Different testing kits produce different titer levels for the same blood sample. In established SLE patients, ANA-negative rates ranged from about 5% to 22% depending on which kit was used. If you switch labs, your titer may shift without any real change in your immune status.
• Reader disagreement: Even among expert lab technicians, agreement on ANA pattern identification is only moderate, with a statistical agreement score of about 0.6 out of 1.0. Cytoplasmic and mitotic patterns are recognized less consistently than nuclear patterns.
• Infections: Various infections, including hepatitis C, can cause transient ANA positivity. In a study of over 9,300 patients with infections, ANA was found in patients with diverse infectious diseases, usually without progression to autoimmune disease.
• Medications: Certain drugs can induce ANA production. Ribavirin (used for hepatitis C) is strongly linked to a specific "rods and rings" pattern (92.3% of patients with this pattern were on ribavirin-containing regimens). Loop diuretics, omeprazole, and ciprofloxacin have been associated with higher ANA prevalence in population data.

Tracking Your Results Over Time

A single ANA pattern result is a snapshot. Because ANA titers can fluctuate with infections, medications, and even normal immune variation, one reading should not drive major decisions on its own. If your result is positive, retesting in 3 to 6 months at the same lab gives you a more reliable picture.

For people with established autoimmune disease, ANA patterns are generally stable, but titers can rise or fall with disease activity. In the SLICC lupus cohort, three different ANA assays showed high agreement in positivity over 5 years, though modest variation in exact titer values. This means your pattern is likely to stay consistent, but the strength of the signal may change. Tracking your titer trend over time is more informative than reacting to any single number.

For people who test positive without symptoms, research suggests that autoantibodies can precede clinical autoimmune disease by years. In a preclinical SLE study, accumulation of ANA specificities and rising levels of immune signaling molecules (called cytokines) appeared well before diagnosis, predicting future disease with 92% accuracy when combined with those signaling profiles. This does not mean every ANA-positive person will develop disease, but it does mean that periodic monitoring, especially with symptoms or family history, is reasonable.